The Choline/creatine Ratio in Five Benign Neoplasms: Comparison with Squamous Cell Carcinoma by Use of in Vitro MR Spectroscopy

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2000 Dec 8

PMID 11110549

Citations 15

Authors

S R Maheshwari

S K Mukherji

B Neelon

S Schiro

G M Fatterpekar

J A Stone

M Castillo

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The choline (Cho)/creatine (Cr) ratio has been shown to be a reliable proton MR spectroscopy metabolic marker for differentiating squamous cell carcinoma (SCCA) from normal muscle in the upper aerodigestive tract. However, it is unclear whether the Cho/Cr ratio can be used to differentiate a malignant tumor from a benign neoplasm in the extracranial head and neck. Our purpose was to determine whether the Cho/Cr ratio can be used to differentiate benign from malignant tumors in this region.

Methods: In vitro one-dimensional proton MR spectroscopy (2,000/136,272 [TR/TE]) was performed at 11 T on tissue specimens obtained from glomus tumors (n = 3), inverting papilloma (n = 1), and schwannoma (n = 1). Cho/Cr area ratios were calculated and compared with similar, previously reported in vitro (11 T) findings and with samples of SCCA and normal muscle.

Results: The Cho/Cr ratio was elevated in relation to muscle in all benign tumors at TE = 136 (glomus tumors = 4.52, inverting papilloma = 3.85, schwannoma = 2.2) and at TE = 272 (glomus tumors = 8.01, inverting papilloma = 2.1, schwannoma = 4.28). The average Cho/Cr ratio for benign lesions was 3.92 (TE = 136) and 6.11 (TE = 272). The Cho/Cr ratio was significantly higher in benign tumors than in both SCCA and muscle. The average Cho/Cr ratio for muscle at TEs of 136 and 272 was 1.16 and 1.31, respectively, whereas for SCCA the average Cho/Cr ratio at TEs of 136 and 272 was 1.67 and 2.45, respectively.

Conclusion: In our small group, the Cho/Cr ratio was significantly higher in benign tumors than in muscle and SCCA of the extracranial head and neck.

Citing Articles

Imaging Findings of an Epidermoid Cyst Undergoing Malignant Transformation.

Chourmouzi D, Papadopoulou E, Karkavelas G, Drevelegas A J Belg Soc Radiol. 2018; 99(1):42-45.

PMID: 30039065 PMC: 6032547. DOI: 10.5334/jbr-btr.829.

Characterisation of musculoskeletal tumours by multivoxel proton MR spectroscopy.

Patni R, Boruah D, Sanyal S, Gogoi B, Patni M, Khandelia R Skeletal Radiol. 2017; 46(4):483-495.

PMID: 28188338 DOI: 10.1007/s00256-017-2573-1.

Metabolomics of Head and Neck Cancer: A Mini-Review.

Shin J, Kamarajan P, Fenno J, Rickard A, Kapila Y Front Physiol. 2016; 7:526.

PMID: 27877135 PMC: 5099236. DOI: 10.3389/fphys.2016.00526.

Future Imaging Alternatives: The Clinical Non-invasive Modalities in Diagnosis of Oral Squamous Cell Carcinoma (OSCC).

Omar E Open Dent J. 2015; 9:311-8.

PMID: 26464601 PMC: 4598385. DOI: 10.2174/1874210601509010311.

Molecular magnetic resonance imaging in cancer.

Haris M, Yadav S, Rizwan A, Singh A, Wang E, Hariharan H J Transl Med. 2015; 13:313.

PMID: 26394751 PMC: 4579835. DOI: 10.1186/s12967-015-0659-x.

References

Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999; 20(9):1619-27. PMC: 7056180. View

Mukherji S, Mancuso A, Kotzur I, Mendenhall W, Kubilis P, Tart R . Radiologic appearance of the irradiated larynx. Part I. Expected changes. Radiology. 1994; 193(1):141-8. DOI: 10.1148/radiology.193.1.8090882. View

Preul M, Caramanos Z, Collins D, Villemure J, LeBlanc R, Olivier A . Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med. 1996; 2(3):323-5. DOI: 10.1038/nm0396-323. View

Negendank W, Brown T, Evelhoch J, Griffiths J, Liotta L, Margulis A . Proceedings of a National Cancer Institute workshop: MR spectroscopy and tumor cell biology. Radiology. 1992; 185(3):875-83. DOI: 10.1148/radiology.185.3.1438779. View

Negendank W . Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5(5):303-24. DOI: 10.1002/nbm.1940050518. View

Russell P, Lean C, Delbridge L, May G, Dowd S, Mountford C . Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant neoplasms. Am J Med. 1994; 96(4):383-8. DOI: 10.1016/0002-9343(94)90071-x. View

Mafee M, Barany M, Gotsis E, DOBBEN G, Puklin J, Chow J . Potential use of in vivo proton spectroscopy for head and neck lesions. Radiol Clin North Am. 1989; 27(2):243-54. View

Krouwer H, Kim T, Rand S, Prost R, Haughton V, Ho K . Single-voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm. AJNR Am J Neuroradiol. 1998; 19(9):1695-703. PMC: 8337475. View

Sivaraja M, Turner C, Souza K, Singer S . Ex vivo two-dimensional proton nuclear magnetic resonance spectroscopy of smooth muscle tumors: advantages of total correlated spectroscopy over homonuclear J-correlated spectroscopy. Cancer Res. 1994; 54(23):6037-40. View

10.

Mackinnon W, Barry P, Malycha P, Gillett D, Russell P, Lean C . Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 1997; 204(3):661-6. DOI: 10.1148/radiology.204.3.9280241. View

11.

Delikatny E, Russell P, Hunter J, Hancock R, Atkinson K, van Haaften-Day C . Proton MR and human cervical neoplasia: ex vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions. Radiology. 1993; 188(3):791-6. DOI: 10.1148/radiology.188.3.8351349. View

12.

van Zijl P, Moonen C, Gillen J, DALY P, Miketic L, Frank J . Proton magnetic resonance spectroscopy of small regions (1 mL) localized inside superficial human tumors. A clinical feasibility study. NMR Biomed. 1990; 3(5):227-32. DOI: 10.1002/nbm.1940030506. View

13.

Mukherji S, Schiro S, Castillo M, Kwock L, Soper R, Blackstock W . Proton MR spectroscopy of squamous cell carcinoma of the upper aerodigestive tract: in vitro characteristics. AJNR Am J Neuroradiol. 1996; 17(8):1485-90. PMC: 8338712. View

14.

Arle J, Morriss C, Wang Z, Zimmerman R, Phillips P, Sutton L . Prediction of posterior fossa tumor type in children by means of magnetic resonance image properties, spectroscopy, and neural networks. J Neurosurg. 1997; 86(5):755-61. DOI: 10.3171/jns.1997.86.5.0755. View

15.

Halliday K, Sillerud L . Differentiation of human tumors from nonmalignant tissue by natural-abundance 13C NMR spectroscopy. Magn Reson Med. 1988; 7(4):384-411. DOI: 10.1002/mrm.1910070403. View

16.

Lean C, Newland R, Ende D, Bokey E, Smith I, Mountford C . Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn Reson Med. 1993; 30(5):525-33. DOI: 10.1002/mrm.1910300502. View

17.

Johnson M, Selinsky B, Davis M, Lawrence T, Cleveland G, Perry J . In vitro NMR evaluation of human thyroid lesions. Invest Radiol. 1989; 24(9):666-71. DOI: 10.1097/00004424-198909000-00004. View

18.

Rand S, Prost R, Haughton V, Mark L, Strainer J, Johansen J . Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol. 1997; 18(9):1695-704. PMC: 8338449. View

19.

Moreno A, Rey M, Montane J, Alonso J, Arus C . 1H NMR spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in tumors may have diagnostic significance. NMR Biomed. 1993; 6(2):111-8. DOI: 10.1002/nbm.1940060202. View

20.

Mukherji S, Schiro S, Castillo M, Kwock L, Muller K, Blackstock W . Proton MR spectroscopy of squamous cell carcinoma of the extracranial head and neck: in vitro and in vivo studies. AJNR Am J Neuroradiol. 1997; 18(6):1057-72. PMC: 8337295. View